Title:
腫瘍標的療法のためのＣＸＣＲ６形質導入Ｔ細胞
Document Type and Number:
Japanese Patent JP7018387
Kind Code:
B2
Abstract:
The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) γδ T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
Inventors:
Kobold, Zebastian
Endless, Stephan
Rap, Moritz
Grassman, Zimon
Endless, Stephan
Rap, Moritz
Grassman, Zimon
Application Number:
JP2018519323A
Publication Date:
February 10, 2022
Filing Date:
October 14, 2016
Export Citation:
Assignee:
Ludwig-Maximilian-Universitat Munich
International Classes:
A61K48/00; A61K35/17; A61K47/46; A61P35/00; A61P37/04; A61P43/00; C12N5/10; C12N15/867
Foreign References:
| US20020076694 | ||||
| WO2015028444A1 | ||||
| US20140271635 |
Other References:
Oncotarget (Mar.29, 2015), Vol.6, No.16, pp.14165-14178
Nature (1997), Vol.388, pp.296-300
Journal of Virology (2005), Vol.79, No.3, pp.1686-1700
Journal of Immunology (2008), Vol.181, pp.3099-3107
Nature (1997), Vol.388, pp.296-300
Journal of Virology (2005), Vol.79, No.3, pp.1686-1700
Journal of Immunology (2008), Vol.181, pp.3099-3107
Attorney, Agent or Firm:
Sonoda/Kobayashi Patent Business Corporation
Previous Patent: Cleaning station for needle nozzles
Next Patent: How to control electromechanical elements
Next Patent: How to control electromechanical elements